Q-omics provides the consensus-scored TNFSF14 profile across patient tissues and cancer cell-line models. TNFSF14 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TNFSF14 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TNFSF14 RNA expression shows 20,916 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where TNFSF14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFSF14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFSF14 survival associations across molecular data types. TNFSF14 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFSF14 RNA expression–survival associations across cancer types. High TNFSF14 expression shows unfavorable associations in KIRC, UVM and LGG, but favorable associations in SKCM, SARC and ACC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TNFSF14 RNA expression.
This table summarizes TNFSF14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TNFSF14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFSF14 shows lower tumor expression in LUSC and BRCA and higher tumor expression in KIRC, KIRP, STAD and HNSC. The KIRC box plot shows higher TNFSF14 RNA expression in tumor versus normal tissue (log2 FC = +1.502, t-test p < 0.001).
This table shows molecular features associated with TNFSF14 in patient tissues and cancer cell lines. In patient samples, TNFSF14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFSF14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
